Matthew G Vander Heiden

Title: Matthew G Vander Heiden: Innovator in Cancer and Metabolic Disease Research

Introduction

Matthew G Vander Heiden is a prominent inventor based in Somerville, MA (US). He has made significant contributions to the fields of cancer and metabolic disease research. With a focus on pyruvate kinase, his work has led to innovative solutions for treating various diseases.

Latest Patents

Matthew G Vander Heiden holds 2 patents that showcase his groundbreaking research. His latest patents include "Inhibitors of pyruvate kinase and methods of treating disease," which provides pharmaceutical compositions, kits, and methods for treating cancer, diabetes, obesity, autoimmune disease, and benign prostatic hyperplasia. This invention utilizes compounds that selectively inhibit pyruvate kinase M2 and includes an assay for measuring chemical modulation of pyruvate kinase activity. Another significant patent is "Activators of pyruvate kinase M2 and methods of treating disease," which features methods, compositions, and kits for using activators of PKM2 to treat, prevent, or ameliorate diseases related to PKM2 function, including cancer, diabetes, atherosclerosis, and obesity.

Career Highlights

Matthew G Vander Heiden is affiliated with Beth Israel Deaconess Medical Center, Inc., where he continues to advance his research. His work has garnered attention for its potential impact on treating complex diseases.

Collaborations

He has collaborated with notable colleagues, including Lewis C Cantley and Heather R Christofk, who share his commitment to advancing medical research.

Conclusion

Matthew G Vander Heiden is a key figure in the innovation of treatments for cancer and metabolic diseases. His patents reflect a dedication to improving health outcomes through scientific research and innovation.